Galectin Therapeutics (GALT) to Release Earnings on Thursday

Galectin Therapeutics (NASDAQ:GALT - Get Free Report) is projected to release its Q1 2025 earnings data before the market opens on Thursday, May 15th. Analysts expect Galectin Therapeutics to post earnings of ($0.20) per share for the quarter.

Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.20) by $0.05. On average, analysts expect Galectin Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Galectin Therapeutics Trading Up 3.9%

Shares of Galectin Therapeutics stock traded up $0.05 during trading on Monday, reaching $1.33. The stock had a trading volume of 180,008 shares, compared to its average volume of 317,040. The company has a market capitalization of $84.03 million, a price-to-earnings ratio of -1.82 and a beta of 0.62. The stock has a fifty day moving average price of $1.41 and a two-hundred day moving average price of $1.63. Galectin Therapeutics has a 52 week low of $0.73 and a 52 week high of $3.28.

Institutional Trading of Galectin Therapeutics

An institutional investor recently raised its position in Galectin Therapeutics stock. Bank of America Corp DE increased its stake in shares of Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) by 101.4% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 38,358 shares of the company's stock after acquiring an additional 19,316 shares during the period. Bank of America Corp DE owned about 0.06% of Galectin Therapeutics worth $49,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 11.68% of the company's stock.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a "neutral" rating on shares of Galectin Therapeutics in a report on Wednesday, April 2nd.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.